Sarcopenia in COPD: a systematic review and meta-analysis. by Benz, Elizabeth et al.
Sarcopenia in COPD: a systematic review
and meta-analysis
Elizabeth Benz1,2,9, Katerina Trajanoska1,2,9, Lies Lahousse 2,3,
Josje D. Schoufour1,2, Natalie Terzikhan2,4, Emmely De Roos 2,4,
Gerdien B. de Jonge5, Ross Williams6, Oscar H. Franco2,7, Guy Brusselle2,4,8
and Fernando Rivadeneira1
Affiliations: 1Dept of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam,
The Netherlands. 2Dept of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam,
The Netherlands. 3Dept of Bioanalysis, FFW, Ghent University, Ghent, Belgium. 4Dept of Respiratory Medicine,
Ghent University Hospital, Ghent University, Ghent, Belgium. 5Medical Library, Erasmus MC, University
Medical Center Rotterdam, Rotterdam, The Netherlands. 6Dept of Medical Informatics, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, The Netherlands. 7Institute of Social and Preventive
Medicine (ISPM), University of Bern, Bern, Switzerland. 8Dept of Respiratory Medicine, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, The Netherlands. 9Both authors contributed equally.
Correspondence: Guy Brusselle, Dept of Epidemiology, Erasmus MC, University Medical Center Rotterdam,
P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands. E-mail: g.brusselle@erasmusmc.nl
@ERSpublications
We confirmed a high prevalence of sarcopenia in COPD patients, with varying prevalence across
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ABSTRACT COPD is associated with a progressive loss of muscle mass and function. However, there is
an unmet need to define and standardise methods to estimate the prevalence of sarcopenia in COPD
patients. We performed a systematic review and meta-analysis of the prevalence of this extrapulmonary
manifestation in COPD patients. We searched Embase, Medline (Ovid), CINAHL (EBSCO), Web of
Science, Scopus and Google Scholar for studies published up to January 17, 2019, assessing sarcopenia in
COPD patients based on low muscle mass and decreased muscle function. Interventional studies, in vitro
experiments, protocols or reviews and meta-analyses were excluded. We estimated heterogeneity (I2) and
assessed significance (Q) using a Chi-squared test for estimates obtained from random-effects models.
4465 articles were initially identified. After removing the duplicates and applying the selection criteria,
we reviewed 62 full-text articles. Finally, 10 articles (n=2565 COPD patients) were included in this
systematic review and meta-analyses. Overall, the prevalence of sarcopenia in patients with COPD was
21.6% (95% CI 14.6–30.9%, I2=94%), ranging from 8% in population-based to 21% in clinic-based studies,
and 63% in COPD patients residing in nursing homes.
Sarcopenia is frequently observed in COPD patients, with varying prevalence across population settings.
Sarcopenia in COPD should be assessed using standardised tests and cut-off points from sarcopenia
consensus criteria for clinical practice and international comparisons.
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Introduction
COPD is a heterogeneous, complex and multisystem disease, with a vast number of intra- and
extrapulmonary manifestations [1–5]. The clinical assessment of COPD patients is also complicated by the
presence of multi-morbid conditions due to shared risk factors with other diseases [3, 6]. The
extrapulmonary manifestations are increasingly recognised as important contributors to functional decline
in patients with COPD [2, 3]. Functional impairment is associated with muscle weakness and body weight
loss in COPD patients [5–7]. Irrespective of the method used to assess muscle mass [8], it is well known
that patients with COPD suffer from loss of muscle mass [9–29]. Indeed, loss of muscle mass and muscle
strength can be greater in patients with moderate-to severe COPD [7, 30] or during acute COPD
exacerbations [31], especially loss of muscle from the lower limbs [6, 7, 32].
Low muscle mass and loss of muscle function have been described as the main components of sarcopenia
[33–38], which was originally defined as a multifactorial geriatric syndrome [39]. However, there has been
increasing recognition of this muscle disorder as a disease-related rather than just age-related condition
[40]. The 2018 European Working Group of Sarcopenia in Older People (EWGSOP2) have reinforced the
importance of distinguishing “secondary sarcopenia” when factors other than ageing are involved from
“primary sarcopenia” or age-related sarcopenia [38]. Sarcopenia can result from underlying diseases such
as COPD or other conditions characterised by chronic inflammation [38]. Although COPD occurs mainly
in middle-aged and older people, sarcopenia in COPD can occur independent of age [41]. Therefore, early
detection of sarcopenia might be pivotal, given that it has therapeutic implications such as pulmonary
rehabilitation and management of respiratory failure in COPD patients.
Although many aspects of the pathophysiology of sarcopenia are better understood now than a decade ago
[38], the precise aetiology of sarcopenia and underlying explanatory mechanisms are still not fully
established [42, 43]. However, physical inactivity, weight loss, inflammatory cytokines, inadequate energy
intake, oxidative stress and reduced blood flow to muscles are common features linked with sarcopenia
[43] as well as COPD [3, 5, 44]. For instance, it is well known that limb muscle dysfunction in COPD
contributes to loss of muscle strength [7]. Despite the heterogeneity in the muscle fibre proportions in
COPD patients [45], there is a shift from type I to II fibres, which correlates inversely with disease severity
[7]. By contrast, age-related loss of muscle strength and mass are mainly attributed to muscle fibre
denervation and loss of type II fibres [46].
In the last decade, different international consensus criteria of sarcopenia [33–38] have focused clinically
and operationally on the measurements and thresholds of sarcopenia (table 1). For instance, five out of six
sarcopenia consensus statements recommend muscle mass measurement as a first criterion to define
sarcopenia. Only the updated EWGSOP2 recommends including muscle strength as the main criterion of
sarcopenia, and labelling the patient as having “probable sarcopenia” [38] when muscle strength is
compromised.
Using these consensus criteria, it has recently been reported that 10% of healthy older adults have
sarcopenia [47]. However, the prevalence of sarcopenia varies widely (0.9%–32.8%) among different study
populations [48]. No global estimates of the prevalence of sarcopenia in COPD patients with the
consensus definitions have previously been reported. Estimating the overall prevalence of sarcopenia,
according to the contemporary operational definitions recommended by multidisciplinary consensus, will
provide further insight into its burden in COPD.
Therefore, we conducted a systematic review and meta-analysis to appraise the best available evidence on
the prevalence of sarcopenia among COPD patients based on the consensus definitions.
Methodology
Search strategy and data sources
This systematic review and meta-analysis adheres to the schema of Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) [49, 50]. We performed an electronic search of
Embase.com, Medline (Ovid), CINAHL (EBSCO), Web of Science, Scopus and Google Scholar to
identify all relevant articles relating to sarcopenia and COPD. We searched all records published from
inception through to January 17, 2019, in collaboration with a medical information specialist (GdJ).
Terms related to COPD (e.g. “chronic obstructive pulmonary disease”) and key terms were combined
with synonyms of sarcopenia (e.g. “muscle atrophy”). We further hand-searched bibliographies of
relevant publications to identify potential articles missed by the principal search. Full search terms are
listed in supplementary table S1.
This systematic review is registered in the International Prospective Register of Systematic Reviews
(PROSPERO), number CDR42018095480.
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Selection criteria
For this systematic review, we used the following inclusion criteria: 1) all studies had to be case–control,
longitudinal or cross-sectional designs; 2) assessment of sarcopenia had to be implemented according to
the sarcopenia consensus criteria (muscle mass and muscle strength or physical performance are
combined); 3) measurement of lean mass or muscle mass had to be assessed by at least one of four main
methods [8] (bioelectrical impedance analysis, dual-energy X-ray absorptiometry, magnetic resonance
imaging or computed tomography); 4) the prevalence of sarcopenia (primary outcome) in COPD patients
had to be reported.
To provide additional insight into the prevalence of sarcopenia in COPD patients, we also investigated the
associations of sarcopenia (if available in the study, e.g. odds ratio) and COPD as a secondary outcome
measure.
We limited our inclusion to original publications, without language restriction, and excluded experimental
studies, reviews and meta-analyses, comments, guidelines, editorials or letters and case reports.
Furthermore, studies that referred to other populations were excluded (i.e. asthma or cystic fibrosis)
(supplementary table S2).
Two independent co-authors (EB and KT) screened all the articles by title and abstract. Disagreements
were resolved by consensus between both co-authors together with a third co-author (LL). The citations
were classified as “eligible”, “uncertain about eligibility” or “excluded” and stored in an EndNote file. The
full text of articles classed as “eligible” and “uncertain about eligibility” was reviewed and appraised
TABLE 1 Criteria and cut-off points to diagnose sarcopenia according to the main consensus criteria groups
Consensus
group
Main criteria definition Lean muscle mass Muscle function
Handgrip
strength
Gait speed m·s−1 SPPB TUG
ESPEN SIG [33] Low muscle mass plus low gait
speed
2SD below mean of young
adults of the same sex
and ethnic background
<0.8 (4MGS)
EWGSOP [34] Low muscle mass plus low muscle
strength or low gait speed
ASMI: Male <30 kg <0.8 (4MGS) ⩽8
DXA score Female <20 kg
Male ⩽7.26 kg·m−2
Female ⩽5.54 kg·m−2
(2SD below mean of young
adults)
BIA score:
Male 8.87 kg·m−2
Female 6.42 kg·m−2
(2SD below mean of young
adults)
IWGS task force
[35]
Low ASMI plus low gait speed ASMI: <1 (4MGS)
Male ⩽7.23 kg·m−2
Female ⩽5.67 kg·m−2
FNIH [36] Low ALM/BMI plus low handgrip ALM/BMI Male <26 kg <0.8 (4MGS, 6MWT)
Male <0.789 Female <16 kg
Female <0.512 kg/BMI
Male <1
Female <0.56
AWGS [37] Low ASMI plus low gait speed or
low handgrip
ASMI: Male <26 kg ⩽0.8 (6MWT)
Male ⩽7.0 kg·m−2 Female <18 kg
Female ⩽5.4 kg·m−2
EWGSOP2 [38] Low muscle strength plus low
muscle mass; severity of
sarcopenia involve low physical
performance
ASMI: Male <27 kg ⩽0.8 ⩽8 ⩾20 s
Male <7.0 kg·m−2 Female <16 kg
Female <5.5 kg·m−2
SPPB: Short Physical Performance Battery; TUG: timed up and go test; ESPEN SIG: European Society of Clinical Nutrition and Metabolism
Special Interest Group (“cachexia-anorexia in chronic wasting diseases”); EWGSOP: European Working Group on Sarcopenia in Older People;
IWGS: International Working Group on Sarcopenia; FNIH: Foundation for the National Institutes of Health; AWGS: Asian Working Group on
Sarcopenia; 4MGS: 4-min gait speed; ASMI: appendicular skeletal muscle mass index; DXA: dual-energy X-ray absorptiometry; BIA:
bioelectrical impedance analysis; BMI: body mass index; ALM: appendicular lean mass; 6MWT: 6-min walk test.
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independently by two co-authors (EB and KT), and disagreements were solved through revision and
consultation with a fourth independent co-author ( JDS).
Data synthesis
We used a predefined data collection form in which we summarised relevant information on
characteristics of the study population (age, sex, setting), outcome assessment (prevalence of sarcopenia,
definition of sarcopenia using any of the consensus criteria, cut-off points, and methods to measure
handgrip and mass muscle) and the effect estimate of association (if available in the study; odds ratio
adjusted for most confounders) with the corresponding precision estimate (95% confidence interval).
When relevant data were not available, the corresponding authors of the selected publications were
contacted to complement the electronic searches.
Risk of bias assessment
We assessed the quality of the selected studies using an adapted version of the scale developed by HOY
et al. [51] for prevalence estimates. The tool consists of 10 items addressing external and internal validity.
Moreover, we used an adapted Newcastle–Ottawa Scale [52] for cross-sectional studies that measured
association between prevalence of sarcopenia and COPD. Two co-authors (EB and KT) independently
rated each of the items of both scales into a global score adding all the items rated as low risk. Therefore,
higher scores indicated lower risk of bias (supplementary table S3).
Statistical analysis
We summarised prevalence of sarcopenia across studies as its estimator (prevalence) and confidence
intervals and present data in tables of study characteristics.
Meta-analysis on the prevalence of sarcopenia in COPD patients was undertaken using a random-effects
model, using the packages meta and metaprop in R (version 3.5.1; R Foundation for Statistical Computing,
Vienna, Austria).
Heterogeneity across studies was defined by an I2 of >50% [53]. Given that the preliminary analyses
demonstrated high heterogeneity, we stratified our analysis by population setting to explore potential
sources of heterogeneity. We used a funnel plot adjusted for population setting to also measure publication
bias [54].
Results
Search results
Our search yielded 4465 records, of which 2315 duplicates were removed, resulting in 2150 unique articles.
We read the full text of 62 articles, and determined that 10 of them were eligible for inclusion in this
meta-analysis (figure 1) [55–64].
Characteristics of studies included
Among the 10 eligible studies published between 2012 and 2018, six were performed only in COPD
patients without a control group [55–57, 59, 60, 63], two reported data on population-based prevalence
[58, 61] and two were nursing home based [62, 64]. Four studies were from Europe [55, 58, 63, 64], four
from Asia [57, 59, 60, 62] and two from South America [56, 61]. The total number of COPD participants
involved in all selected studies was 2565, with a mean age ranging from 62 to 84 years at study entry (table 2).
Eight of the selected studies used the EWGSOP definition of sarcopenia [55, 58–64], and two of them
applied the Foundation for the National Institutes of Health (FNIH) and the Asian Working Group on
Sarcopenia consensus (table 1) [56, 57]. When we analysed the components of sarcopenia in these
10 studies, we found large variability in the methods and cut-off points, especially for lean mass. All these
studies assessed lean mass by dual-energy X-ray absorptiometry or bioelectrical impedance rather than
magnetic resonance imaging or computed tomography, although one used calf circumference to measure
lean mass (table 2) [61].
Quality assessment
Quality assessment scores of all included observational studies are listed according to prevalence, and two
of them according to association estimators (supplementary tables S4 and S5). Regarding methodological
quality of the prevalence estimator, seven (70%) had moderate risk of bias and three (30%) had low risk
of bias.
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Prevalence of sarcopenia in COPD patients
The prevalence of sarcopenia in COPD patients ranged from 7.9% to 66.7%. There was substantial
heterogeneity between studies (I2=94%, p<0.01), which could largely be accounted for by two studies [62,
64]. These two nursing home-based studies, which had the smallest combined sample size (n=46 COPD
patients) of any study included, reported the highest prevalence of sarcopenia. When excluding these
studies in a sensitivity analysis, the prevalence of sarcopenia was 16.5% (95% CI 11.4%–23.2%), with high
heterogeneity (I2=92%, p<0.01) (supplementary figure S1).
Therefore, we included the 10 studies and stratified our analysis according to the three main population
settings: 1) clinic based, 2) population based and 3) nursing home based. Stratifying our analysis resulted
in a reduction of heterogeneity within the three population settings. Consequently, the pooled prevalence
of sarcopenia was 21.6% (95% CI 14.6%–30.9%) (figure 2 and supplementary table S6). There was
symmetry for the funnel plot describing publication bias in these 10 selected studies when stratified by
population setting (supplementary figure S2).
Additionally, we meta-analysed all the excluded studies that measured only the lean mass component of
sarcopenia given that, prior to 2010, having a low lean mass was considered to represent sarcopenia
(figure 1) [34, 38, 40]. These studies applied two main muscle indices: appendicular skeletal muscle mass
index (ASMI), also referred as skeletal mass index (SMI) [9–15], and fat-free mass index (FFMI) [16–29].
The prevalence of low lean mass based on ASMI in COPD patients was 31.0% (95 CI 28.2%–34.2%,
I2=65%, p<0.01). According to FFMI, the prevalence of low lean mass in COPD patients was 23.4% (95%
CI 18.6%–29.0%, I2=96%, p<0.01) (supplementary figure S3; supplementary tables S7, S8, S9). After
performing this division by index muscle, the I2 statistics (65% and 96% respectively, p<0.01), although
lower than when using the sarcopenia consensus criteria, still indicated heterogeneity.
Association of sarcopenia and COPD
In addition to the prevalence of sarcopenia described in the aforementioned studies, despite the
considerable variation of the cut-off points, the association of sarcopenia with COPD was tested in two
studies. BORDA et al. [61] investigated the association of sarcopenia in 250 COPD/asthma participants, and
Potentially eligible records identified through
database searching
Embase: 1377
Medline (Ovid): 1017
CINAHL (EBSCO): 296
Web of Science: 666
Scopus: 909
Google Scholar: 200
Total: n=4465
Additional records
identified from citation
lists: n=1
2150 screened on the basis of title
and abstract 
2315 duplicates excluded
62 full-text articles assessed for
eligibility
52 full-text articles excluded:
21 based only on lean mass
10 no prevalence reported
  7 non-COPD patients/population
  5 different measurements
  3 review articles
  3 non-stable COPD
  2 only muscle strength
  1 duplicate
2089 excluded
10 full-text articles selected
6 studies
clinic-based
2 studies
population-based
2 studies nursing
home-based
Sub-analysis of 21 excluded 
studies that measured sarcopenia 
based only on lean mass:
14 based on FFMI
  7 based on ASMI or SMI
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FIGURE 1 Flow diagram of the study selection process. FFMI: fat-free mass index; ASMI: appendicular
skeletal muscle mass index; SMI: skeletal muscle mass index.
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TABLE 2 Main characteristics of the cross-sectional selected studies in the meta-analysis
First author
[ref.]
Country Subjects n Male Age years Setting Consensus
group
Prevalence % (n)
Components of sarcopenia
Lean mass Muscle strength Physical performance
Method Cut-off Method Cut-off kg Method Cut-off m·s−1
DE BLASIO [55] Italy COPD: 263 70.3 69.8±8.0 Clinical EWGSOP 24 (63) BIA (SMI) M: ⩽8.50 kg·m−2
F: ⩽5.75 kg·m−2
HGS NS 4MGS <0.8
MUNHOZ DA ROCHA
LEMOS COSTA
[56]
Brazil COPD: 121 46.3 67.9±8.6 Clinical FNIH 12.4 (15) DXA (ALM/BMI) M: <0.789
F: <0.512
NS 6MWT ⩽0.8
LIMPAWATTANAZ [57] Thailand COPD: 121 92.6 >65 Clinical AWGS 24 (29) DXA (ASMI) M: ⩽7.0 kg·m−2
F: ⩽5.4 kg·m−2
HGS M: 26
F: 18
6MWT <0.8
TRAJANOSKA [58] Netherlands COPD: 882
All population:
5911
69.2±9.1 Population EWGSOP COPD: 7.9 (70)
All population: 4.4
(260)
DXA (SMI) M: ⩽7.25 kg·m−2
F: ⩽5.67 kg·m−2
HGS M: ⩽29 (if BMI ⩽24) GAITRite M: <0.65 (if height ⩽173 cm)
⩽30 (if BMI ⩽24.1–28) <0.76 (if height >173 cm)
⩽32 (if BMI >28) F: <0.65 (if height ⩽159 cm)
F: ⩽17 (if BMI ⩽23) <0.76 (if height >159 cm)
⩽17.3 (if BMI ⩽23.1–26)
⩽18 (if BMI ⩽26.1–29)
⩽21 (if BMI >29)
BYUN [59] Korea COPD: 80 83.8 68.4±8.9 Clinical EWGSOP 25 (20) BIA (SMI) Below 2SD of mean
population
HGS M: ⩽30
F: ⩽20
NS
LIAN [60] China COPD: 96 58.3 62.4±7.9 Clinical EWGSOP 28.1 (27) BIA (SMI) M: ⩽7.01 kg·m−2
F: ⩽5.43 kg·m−2
HGS M: ⩽35.04
F: ⩽21.82
NS
BORDA [61] Colombia COPD/asthma: 334
No COPD/asthma:
1666
32.9 >60 Population EWGSOP COPD/asthma: 11 (28)
No COPD/asthma:
6.9 (77)
CC <31 cm NS 4MGS
TASAR# [62] Turkey COPD: 33
All population:
211
69.7 73.9±7.2 Nursing
home
EWGSOP COPD: 66.7 (22)
All population 33.6
(71)
BIA (FFM/BSA) Below the 20th
percentile of mean
population
HGS M: ⩽30
F: ⩽20
6MWT ⩽0.8
JONES [63] UK COPD: 622 58.8 73±8 Clinical EWGSOP 14.5 (90) BIA (SMI) M: ⩽8.50 kg·m−2
F: ⩽5.75 kg·m−2
HGS M: <30
F: <20
4MGS <0.8
LANDI [64] Italy COPD: 13
All population:
122
68 84±7.3 Nursing
home
EWGSOP COPD: 53.4 (7)
All population: 32.8
(40)
BIA (SMI) M: <8.87 kg·m−2
F: <6.42 kg·m−2
HGS M: <30
F: <20
4MGS ⩽0.8
Data are presented as % or mean±SD, unless otherwise stated. EWGSOP: European Working Group Older People; M: male; F: female; BIA: bioelectrical impedance analysis; SMI: skeletal
muscle index; NS: not specified; HGS: handgrip strength; 4MGS: 4-min gait speed; FNIH: Foundation for the National Institute of Health; DXA: dual-energy X-ray absorptiometry; ALM:
appendicular lean mass; BMI: body mass index; 6MWT: 6-min walk test; AWGS: Asian Working Group on Sarcopenia; ASMI: appendicular skeletal muscle mass index; GAITRite: 5.79-m-long
electronic walkway; CC: calf circumference; FFM: fat-free mass; BSA: body surface area. #: data directly obtained from authors.
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the odds ratio for sarcopenia was 2.01 (95% CI 1.21–3.35), independent of sex, age, educational level and
body mass index (BMI). Moreover, TASAR et al. [62] reported that the odds ratio for elderly people with
COPD to have sarcopenia was 1.69 (95% CI 0.83–3.43).
Factors associated with sarcopenia in COPD patients
Some of the main factors associated with sarcopenia in COPD patients were age [56, 59, 60], especially
among the older group (⩾75 years old) [57]; systemic inflammatory biomarkers (high-sensitivity tumour
necrosis factor-α (hsTNF-α)) [59]; and BMI, either separately (both high [57] and low [59]) or as part of
the BODE index (BMI, airflow obstruction, dyspnoea and exercise) [56] (supplementary table S10).
Smoking, one of the main risk factors for COPD, was associated with sarcopenia in one study [60],
whereas in two other studies it was not [56, 57]. In addition, JONES et al. [63] did not find a difference in
smoking status between COPD patients with and without sarcopenia.
Severity of COPD [57], severity of dyspnoea [57] and cardiovascular disease [59] were the main clinical
outcomes associated with sarcopenia in COPD patients. DE BLASIO et al. [55] reported that 58.7% of
COPD patients with sarcopenia were also malnourished. In the study of JONES et al. [63], COPD patients
with sarcopenia had more severe airflow obstruction (low forced expiratory volume in 1 s (FEV1)) and
reduced physical activity, functional performance and exercise capacity.
When the components of sarcopenia were analysed separately, BYUN et al. [59] found that handgrip and
SMI were negatively correlated with serum interleukin-6 (r= −0.27 and r= −0.23, respectively) and
hsTNF-α (r= −0.35 and r= −0.25, respectively).
Discussion
Overall, we found that ∼22% of individuals with COPD had sarcopenia. The prevalence estimates of
sarcopenia varied between 12.4% and 28.1% in clinical settings, and 7.9% and 8.4% in population-based
settings. Prevalence was highest in nursing home settings, ranging from 53.8% to 66.7%. We observed
large heterogeneity across studies, attributed to important differences in methods and cut-off points used
to assess muscle mass, and particularly the distinct population settings. Therefore, differences between
study settings (i.e. community dwelling versus institutionalised patients) should be considered when
assessing the risk of sarcopenia in COPD patients.
In COPD patients, BONE et al. [42] have previously described the importance of sarcopenia based on
consensus criteria. However, to the best our knowledge, this systematic review including a meta-analysis is
Study Events
Setting=Clinic-based
63
15
29
27
20
90
70
28
22
7
263 24.0 16.2
4.5
7.5
6.6
5.1
26.1
65.9
21.8
8.7
30.5
2.5
1.1
3.6
100.0
--
--
--
10.9
9.9
10.4
10.3
10.0
11.0
--
62.4
11.0
10.5
--
9.0
7.1
--
--
100.0
16.1
21.5
(18.9–29.6)
(7.1–19.6)
(16.7–32.6)
(19.4–38.2)
(16.0–35.9)
(11.8–17.5)
(17.2–21.6)
(15.6–26.6)
(6.2–9.9)
(5.6–11.9)
(6.7–9.7)
(6.7–9.7)
(48.2–82.0)
(25.1–80.8)
(48.1–75.6)
(48.1–75.6)
(14.4–17.5)
(14.6–30.9)
12.4
24.0
28.1
25.0
14.5
19.3
20.6
7.9
8.4
8.1
8.1
66.7
53.8
62.9
62.9
15.9
21.6
121
121
96
80
622
882
334
33
13
1216
46
2565
0 20 20 60
Prevalence of sarcopenia in COPD patients
80 100
1303
Setting=Population-based
Setting=Nursing home-based
Fixed-effect model
Random-effects model
Heterogeneity: I2=80%,   2=0.1339, p<0.01
DE BLASIO [55]
MUNHOZ DA ROCHA LEMOS COSTA [56]
LIMPAWATTANA [57]
LIAN [60]
BYUN [59]
TRAJANOSKA [58]
TASAR [62]
LANDI [64]
BORDA [61]
JONES [63]
Total Prevalence (95% CI) % Weight
(fixed) %
Weight
(random) %
Fixed-effect model
Random-effects model
Heterogeneity: I2=0%,  2=0, p=0.80
Fixed-effect model
Random-effects model
Fixed-effect model
Random-effects model
Heterogeneity: I2=0%,  2=0, p=0.42
Residual heterogeneity: I2=72%, p<0.01
Heterogeneity: I2=94%,  2=0.5320, p<0.01
FIGURE 2 Fixed- and random-effects meta-analysis results for the prevalence of sarcopenia in patients with COPD, according to population
setting. The authors directly provided the prevalence estimate for the study by TASAR et al. [62].
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the first to assess the prevalence of sarcopenia in patients with COPD. This meta-analysis notes the
heterogeneity induced by the different methods used to assess sarcopenia and the type of population setting.
Clinic-based studies
The vast majority of the selected studies reporting prevalence of sarcopenia in COPD patients were clinic
based, with high heterogeneity between studies (I2=80%, p<0.01). Notably, two studies using the same
cut-off points and methods to measure sarcopenia in COPD patients [55, 63] reported prevalence
estimates with big discrepancies (∼10% difference). However, the study by DE BLASIO et al. [55]
(n=263) included more male COPD patients (70%), and the sarcopenic group (n=26) had more
deteriorated lung function (FEV1 % pred 30.9%, 95% CI 26.1%–35.7%) than that of JONES et al.
[63] (n=622) (sarcopenic group (n=90), FEV1 % pred 43.5%, 95% CI 37.4%–50.2%).
Population-based studies
The prevalence of sarcopenia in COPD population-based studies was lower than in clinical settings. This
finding can be explained by the fact that COPD cases from the population are more often in an early stage
of the disease or even asymptomatic. Two population-based studies reported the prevalence of sarcopenia
in COPD [58, 61]; although they used the same consensus criteria [34], there was no uniformity in the
measurement methods used, particularly for lean mass. TRAJANOSKA et al. [58] performed a specific
calculation of each component of sarcopenia, based on BMI and height, for male and female patients. By
contrast, BORDA et al. [61] calculated low lean mass based on calf circumference for both sexes in patients
with COPD/asthma. This makes comparison between the two studies difficult.
Nursing home-based studies
The high prevalence of sarcopenia in COPD patients from nursing homes can be explained by two main
factors. First, the selected studies had small sample sizes (<50 participants). Second, according to the mean
age, these participants were older than the age range mean of the clinic- and population-based studies.
However, while the prevalence of sarcopenia increases notably with ageing, the high prevalence within
COPD patients is unlikely to be explained by age alone. There are biological mechanisms by which
respiratory impairment contributes to muscle deterioration [7], e.g. patients with more severe emphysema
have lower muscle mass [30].
Sarcopenia consensus statements
We found six international sarcopenia consensus criteria that can be applied in clinical and research fields
[33–38]. All of these criteria are based on lean mass and physical performance related to muscle loss, but
there is still a lack of uniformity in measurement standards, and especially in cut-off points across these
criteria. However, the cut-off points for lean mass and handgrip strength measurements from two of the
consensus criteria (EWGSOP2 and FNIH) are practically equivalent [36, 38].
The majority of our selected studies (n=8) [55, 58–64] applied the EWGSOP criteria to define sarcopenia
in COPD patients. According to the updated EWGSOP2 [38] recommendations, muscle strength can be
considered as the principal determinant of sarcopenia, mainly because it can facilitate early identification
of sarcopenia in clinical practice. EWGSOP2 have modified and simplified the cut-off points to identify
primary and secondary sarcopenia in a broad population [40]. Consequently, we suggest using the
EWGSOP2 practical algorithm for case finding, diagnosis of sarcopenia and determining sarcopenia
severity in COPD patients. We encourage clinicians to start by systematically assessing handgrip in all
COPD patients, which is easily performed, rather than with other tests that can be influenced by COPD
due to ventilator restrictions.
To classify the severity of sarcopenia, EWGSOP2 recommends different tests, e.g. gait speed, 400-m walk
test, Short Physical Performance Battery and timed up and go test (TUG), with corresponding cut-off
points. In COPD patients, an optimal test should be targeted for each case. For instance, the TUG test has
not been associated with airflow limitation, in contrast to the 6-min walk distance [65]. Therefore, the
TUG test could be implemented in cases of COPD with more severe ventilatory impairment. Similarly, a
cut-off point (11.2 s) different from the EWGSOP2 recommendation (20 s) has been suggested for use as
an abnormal TUG time for COPD patients [66]. Nevertheless, additional studies are needed to establish
which functional test and cut-offs should be used across different stages of COPD. Given that these
updated recommendations have only recently been introduced, their performance within COPD patients
has not yet been performed and warrants future studies.
When we analysed each element of sarcopenia across studies, muscle mass was the component with most
variability in its measurements, mainly due to muscle indices and cut-off points. For instance, in Asian
populations, BYUN et al. [59] used a SMI below 2SD of the mean of the Korean population, whereas
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LIAN et al. [60] used cut-offs close to the ASMI. To diagnose sarcopenia in patients with COPD, dual
X-ray absorptiometry and bioelectrical impedance analysis were used to measure lean mass. However, no
consensus has been reached concerning cut-off points of lean mass across different international (working)
groups for the diagnosis of sarcopenia. Therefore, for both SMI and ASMI, the cut-off points require
further validation and standardisation. There is more consistency across the sarcopenia consensus criteria
groups for assessing muscle function, although a wide range of cut-off points have been recommended
(e.g. handgrip in males ranges from 26 kg to 30 kg). In addition, cut-offs for gait speed were essentially the
same (⩽ or <0.8 m·s−1). Only the method to measure gait speed differed across studies: some articles used
the 6-min walk test and others 4-m gait speed (m·s−1). However, 4-m gait speed is significantly correlated
with the 6-min walk test in COPD patients [67]. Studies are required to further establish the role and
interaction of each sarcopenia component in COPD patients.
Factors associated with sarcopenia in COPD patients
We only found two studies that reported an association between sarcopenia and COPD [58, 61], even after
adjustment for age, sex and BMI. Additionally, TRAJANOSKA et al. [58] reported that the difference in
sarcopenia prevalence between COPD and non-COPD individuals was independent of age, sex, smoking
and corticosteroid use.
Multiple factors were associated with the presence of sarcopenia in COPD patients in the selected studies.
These factors included age, severity of COPD, BMI, BODE index, dyspnoea and elevated inflammatory
biomarkers, such as TNF-α [56, 57, 59, 60]. However, the direct effect of smoking on sarcopenia, an
established risk factor for COPD, showed different associations across studies. For instance, only one study
[60] reported an association between smoking and sarcopenia among COPD patients, whereas two other
studies did not [56, 57]. Likewise, in support of a negative association, another study did not find
differences in smoking across COPD patients with and without sarcopenia [63]. One explanation for these
discrepancies might originate from distinct smoking classification across studies; while LIAN et al. [60] used
cumulative smoking exposure (i.e. a long-term history of smoking, defined as ⩾10 cigarettes/day for
10 years), all other studies categorised smoking status as never, past and current.
None of these studies reported sex differences in the prevalence of sarcopenia, in contrast to what has been
shown in previous studies on COPD patients that mainly focused on lean mass (and not on sarcopenia)
[13, 22]. Moreover, COPD patients with sarcopenia had lower FEV1, lower exercise capacity and lower
physical activity than patients without sarcopenia [63]. Therefore, in terms of sarcopenia in COPD
patients, factors including age, severity of COPD, BMI, BODE index, dyspnoea and hsTNF-α might add
value to preventive strategies, especially when these strategies are modifiable. Likewise, other factors such
as corticosteroid use, protein intake and alcohol use were not considered and as such these should be of
interest for future research.
CRUZ-JENTOFT et al. [38] consider sarcopenia as “secondary” when another factor besides ageing is present.
They state that secondary sarcopenia can occur due to a systemic disease (i.e. COPD), physical inactivity
and inadequate energy intake, among other factors [38]. However, there is not any distinction in
recommendations of methods and cut-offs for distinguishing primary and secondary sarcopenia. It is
important to consider that across these selected studies, age was associated with sarcopenia, which is also
in line with the fact that COPD patients with sarcopenia are older. Only one study did not find age
differences in COPD patients with and without sarcopenia [55]. Nevertheless, patients in all of these
studies were aged >60 years. Therefore, an overlap between primary and secondary sarcopenia in COPD
patients can be expected and is difficult to differentiate. Additionally, sarcopenia is increasingly recognised
as a progressive and generalised muscular disorder related to long-term conditions presenting during
midlife, such as COPD [40]. Nevertheless, sarcopenia in COPD patients seems to be more disease-related
than age-related, as supported by distinct physiopathological processes related to ageing and COPD. With
ageing there is a transition of the muscle fibres from type II to type I [68], involving intra- and
inter-muscular adipose tissue [69]. In contrast, in COPD there is mainly a shift from type I to type II
fibres [7] that can be responsible for dyspnoea symptomatology and/or low performance during exercise
tests. Further understanding of the main molecular and cellular mechanisms underlying the onset of
sarcopenia in COPD patients could support the optimisation of assessment tools for sarcopenia in COPD.
Strengths of this systematic review include the use of a predefined protocol, a comprehensive search
strategy and the involvement of two independent co-authors in all stages of the process. Nevertheless, it is
not free of limitations, and several topics should be taken into account when interpreting our results. First,
as was previously highlighted, despite our results being centred around all sarcopenia consensus criteria,
the cut-off points for its components were not uniform across studies. One explanation might be that
there were different indices to measure muscle mass, and consequently there were different cut-offs. For
instance, despite most of the selected studies used EWGSOP consensus criteria, they used different indices
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to measure lean mass (appendicular lean mass/height2, skeletal muscle mass/height2, fat-free mass/body
surface area); they also applied different cut-offs even for the same muscle index. Another explanation may
be that they used different dual-energy X-ray absorptiometry and bioelectrical impedance analysis devices
to measure lean mass. It is well known that bioelectrical impedance analysis, an inexpensive alternative
to dual-energy X-ray absorptiometry, is dependent on the formula used [70], which differed among these
studies. It has also been widely reported that dual-energy X-ray absorptiometry and bioelectrical
impedance measurements in healthy adults provide different estimates of fat mass and fat-free mass [71].
Second, the main aim of this systematic review and meta-analysis was to provide a comprehensive
overview of the current overall prevalence of sarcopenia in COPD patients, independent of the population
setting. However, the six clinic-based studies used different consensus criteria and were performed in
different ethnic groups, resulting in different estimates of sarcopenia prevalence. Similarly, the two
population-based studies used different cut-offs and measurements, as did the nursing home studies, and
the quality assessment of the selected studies varied, affecting the external validity. Therefore, our results
may not be representative for COPD patients in general. Likewise, our results highlight that
population-based studies on the association of main lifestyle factors (e.g. diet, physical activity, smoking)
with sarcopenia in COPD patients remain limited.
More studies are needed to identify the main characteristics of COPD patients who present with
sarcopenia defined by low muscle mass and function. This is particularly the case given that the updated
EWGSOP2 recommendations mention that healthcare professionals have increasing possibilities for
preventing, delaying, treating and even reversing sarcopenia [38]. EWGSOP2 have described that low
muscle strength should be considered as “probable sarcopenia”. Therefore, systematically measuring the
handgrip of each COPD patient, independent of the clinical setting, can contribute to early detection,
prevention and treatment of sarcopenia. Muscle strength is determined by the velocity and type of
contraction, size and motor units activated [7], which are affected early in COPD patients [7]. However,
this does not mean that we should consider only handgrip for early detection of sarcopenia in patients
with COPD, because the relationship between muscle mass and muscle function is nonlinear [72]. In
addition, according to new recommendations of the Global Leadership Initiative on Malnutrition [73],
having low muscle mass with normal muscle strength would be considered to be a result of malnutrition
rather than sarcopenia.
We propose that the EWGSOP2 algorithm be used in clinical practice [38], and muscle strength assessed
in all COPD patients. We call for more research directed towards defining optimal cut-off points of tests
measuring muscle mass or function in patients with COPD. Importantly, multidisciplinary interventions
such as pulmonary rehabilitation, which is included in the EWGSOP2 algorithm, have been shown to
improve physical performance and exercise capacity in patients with COPD. The different steps of the
TABLE 3 EWGSOP2 algorithm for case finding, making a diagnosis and quantifying severity of sarcopenia in clinical practice
with clinical and research considerations for COPD patients
Steps Components Response Considerations for COPD patients
Step 1: Case finding SARC-F or clinical suspicion +: Go to step 2 SARC-F in all COPD patients
−: No sarcopenia, rescreen
later
Step 2: Assess Muscle strength (grip strength
or chair stand test)
+: Go to step 3 plus start
intervention: “probable
sarcopenia”
Call for research directed to define accurate cut-off
points for low muscle strength in COPD patients
−: No sarcopenia, rescreen
later
Step 3: Confirm Muscle quantity or quality
(DXA, BIA, CT, MRI)
+: Go to step 4 plus
intervention: “sarcopenia”
Call for research directed to define accurate cut-off
points for low muscle mass in COPD patients
−: Intervention for “probable
sarcopenia”
Step 4: Severity Physical performance (gait
speed, SPPB, TUG, 400 m
walk)
+: “Severe sarcopenia” Call for research directed to define optimal physical
performance tests and accurate cut-off points for
COPD patients
−: Intervention for “sarcopenia”
EWGSOP2: 2018 European Working Group Older People; SARC-F: questionnaire with the five components of strength, assistance with walking,
rise from a chair, climb stairs and falls; DXA: dual-energy X-ray absorptiometry; BIA: bioelectrical impedance analysis; CT: computed
tomography; MRI: magnetic resonance imaging; SPPB: Short Physical Performance Battery; TUG: timed up and go test.
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diagnostic approach to sarcopenia in patients with COPD, encompassing case finding, assessment,
confirmation and determining its severity, are illustrated in table 3.
Finally, it is important to highlight that we found the overall prevalence of sarcopenia in COPD patients to
be twice as high as compared to a healthy elderly population. In conclusion, sarcopenia defined as low
muscle mass plus reduced muscle function is a frequent extrapulmonary condition in COPD patients.
Despite the sarcopenia consensus criteria, there is still a lack of agreement in the optimal method and
cut-off points to assess sarcopenia in general and in COPD patients in particular. Therefore, it is necessary
to standardise the assessment methods for clinical practice and future research in COPD patients.
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